Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer

LSD1, an epigenetic modifier, and PELP1, an estrogen receptor co-activator, integrate estrogen receptor ERα and HER2 receptor tyrosine kinase signaling to promote aromatase expression and hormone resistance in a preclinical model of post-menopausal breast cancer. In the previous issue of Breast Canc...

Descripción completa

Detalles Bibliográficos
Autor principal: Bennani-Baiti, Idriss M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053100/
https://www.ncbi.nlm.nih.gov/pubmed/22992372
http://dx.doi.org/10.1186/bcr3249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053100/
https://www.ncbi.nlm.nih.gov/pubmed/22992372
http://dx.doi.org/10.1186/bcr3249

Ejemplares similares